
News|Articles|February 13, 2019
Xospata for Relapsed or Refractory AML
Author(s)Drew Boxler
Advertisement
Xospata (gilteritinib, Astellas)
Indications: Adult patients with relapsed or refractor acute myeloid leukemia (AML) with an FLT3 mutation.
Dosage: 120 mg orally once-daily; 40 mg tablets
Contraindications: Hypersensitivity to gilteritinib or any of the excipients. Naphylactic reactions have been observed in clinical trials.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Hormone Replacement Therapy May Lower Dementia Risk in Postmenopausal Women
3
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
4
AI, Automation Are Transforming Pharmacies into Proactive Care Hubs
5







































